Guidelines for the design of pivotal psychiatric drug trials used in new drug applications are produced by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Who is involved in the development of the guideline and what specific trial design recommendations they provide are unknown. A cross-sectional investigation of the FDA Guidance Documents and the EMA Clinical Efficacy and Safety Guidelines. Results of the study: 1) declared conflicts of interest among members of the guideline committee; 2) the creation of guidelines and the arrangement of the commenting phases; 3) categorisation of partners who remark on draft and last rules as per irreconcilable circumstances ('industry', 'notindustry however with industry-related clashes', 'autonomous', 'indistinct'); and (4) recommendations for the trial design.
HTML PDFShare this article
Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report
